Abstracts tagged "pulmonary complications and risk assessment"

Abstract Number: 98 • 2012 ACR/ARHP Annual Meeting
How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study
Hayato Yamazaki¹, Ryoko Sakai¹, Ryuji Koike², Yasunari Miyazaki³, Michi Tanaka¹, Toshihiro Nanki¹, Kaori Watanabe¹, Shinsuke Yasuda⁴, Takashi Kurita⁵, Yuko Kaneko⁶, Yoshiya Tanaka⁷, Yasuhiko Nishioka⁸, Yoshinari Takasaki⁹, Kenji Nagasaka¹⁰, Koichi Amano¹¹, Shigeto Tohma¹², Makoto Dohi¹³, Takahiko Sugihara¹⁴, Haruhito Sugiyama¹⁵, Yasushi Kawaguchi¹⁶, Naohiko Inase¹⁷, Sae Ochi¹⁸, Hiroyuki Hagiyama¹⁹, Nobuyuki Miyasaka²⁰ and Masayoshi Harigai²¹, ¹Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ²Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁵Department of Medicine II, Hokkaido University, Sapporo, Japan, ⁶Dept of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Respiratory Medicine & Rheumotology, The Univeristy of Tokushima Graduate School, Tokushima, Japan, ⁹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁰Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹²Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, ¹³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ¹⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁵Division of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan, ¹⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷Dept of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁸Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, ¹⁹Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, ²⁰Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ²¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Patients with rheumatic diseases given immunosuppressive therapy are susceptible to various types of infections, especially pulmonary infections that affect their vital prognosis. The aim…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].